Compare Crispr Therapeutics AG (CRSP) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Thomson Reuters Corp — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while Thomson Reuters Corp trades at $104.52 (market cap $45.38B). The key difference: Thomson Reuters Corp is far larger — about 8.7× Crispr Therapeutics AG's market cap, and Thomson Reuters Corp pays a 2.5% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TRI | |
|---|---|---|
Market Cap | $5.23B | $45.38B |
Sector | Health | Industrials |
52-Week High | $76.78 | $178.77 |
52-Week Low | $44.34 | $76.55 |
Enterprise Value | $3.65B | $48.00B |
Dividend Yield | — | 2.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
